CTLA4 and Autoimmunity: Despite promising evidence (30), targeting CD28 in autoimmunity has not reached common clinical use, and especially for rheumatoid arthritis (RA), the focus has been on targeting CTLA-4, which also binds CD80, and competes with CD28 (31).